Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Aurobindo Pharma to Acquire Generics Business of Apotex 13
Novartis May Sell US Generic Pill Business 14
Aurobindo Pharma May Acquire Dermatology Generics Business from Novartis 16
Aurobindo Pharma May Acquire Russian Business of Shreya Life Sciences 17
Intas Pharma and Aurobindo Pharma May Acquire Europen Divisions from Teva Pharma 18
Mallinckrodt May Sell Generic Drug Unit to Aurobindo Pharma 19
Aurobindo Pharma Acquires Four Biosimilar Products from TL Biopharma 20
Arrow Generiques to Acquire Select Commercial Products in France from Teva Pharma 21
Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 22
Aurobindo Pharma Completes Acquisition Of Generics Operations Of Actavis In Western Europe For US$40.8 Million 23
Partnerships 25
Aurobindo Pharma Forms Joint Venture with Tergene Biotech 25
Celon Labs Forms Joint Venture with Aurobindo Pharma 26
Licensing Agreements 27
Aurobindo Pharma, Cipla, Desano Pharma, Emcure Pharma, Hetero Labs and Laurus Labs Enter into Licensing Agreement with Medicines Patent Pool 27
Aurobindo Pharma Extends its Licensing Agreement with Medicines Patent Pool 29
Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool 30
Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool for Lopinavir/Ritonavir 31
Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 32
Equity Offering 34
Aurobindo Pharma Plans to Raise USD300 Million in Private Placement of Shares 34
Aurobindo Pharma Receives Board Approval for Private Placement of Shares for up to USD350 Million 35
Asset Transactions 36
Aurobindo Pharma Sells Manufacturing Facility In Tamilnadu 36
Acquisition 37
Aurobindo Pharma to Acquire Additional 20% Stake in Tergene Biotech 37
Agile Pharma Acquires Generis Farmaceutica from Magnum Capital Partners for USD142.8 Million 38
Eris Pharma Acquires Aurobindo Pharma Australia from Aurobindo Pharma 39
Aurobindo Pharma Acquires Natrol for USD132.5 Million 40
Aurobindo Pharma Acquires Hyacinths Pharma for up to USD3 Million 41
Aurobindo Pharma Acquires Remaining 25% Stake in Silicon Life Sciences from ABS Mercantiles 42
Aurobindo Pharma Ltd – Key Competitors 43
Aurobindo Pharma Ltd – Key Employees 44
Aurobindo Pharma Ltd – Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Joint Venture 48
Recent Developments 49
Financial Announcements 49
May 28, 2018: Aurobindo Pharma Q4 FY17-18 and FY17-18 Financial Results 49
Nov 09, 2017: Aurobindo Pharma: Q2 FY17-18 Financial Results 51
Aug 09, 2017: Aurobindo Pharma: Consolidated Financial & Business Highlights – Q1FY18 53
Feb 09, 2017: Aurobindo Pharma Announces Q3 results & Limited Review Report for the Quarter ended December 31, 2016 54
Corporate Communications 55
Feb 09, 2017: Aurobindo Pharma Announces Change in Board of Directors 55
Legal and Regulatory 56
Mar 05, 2018: Aurobindo Pharma Issued Clarification on US FDA Observations 56
Mar 05, 2018: Aurobindo Announces Inspection of Unit 4 by US FDA 57
Mar 04, 2018: US inspectors cite serious quality issues at Aurobindo Pharma’s Unit 4 58
Apr 19, 2017: Aurobindo Pharma Provides Update on US FDA Inspection at Bachupally Manufacturing Facility 59
Product News 60
May 13, 2018: Aurobindo Pharma’s arm recalls 2 antibiotic injections from US 60
03/30/2017: Aurobindo Pharma receives USFDA Approval for Generic Epzicom tablets 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aurobindo Pharma Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Aurobindo Pharma to Acquire Generics Business of Apotex 13
Novartis May Sell US Generic Pill Business 14
Aurobindo Pharma May Acquire Dermatology Generics Business from Novartis 16
Aurobindo Pharma May Acquire Russian Business of Shreya Life Sciences 17
Intas Pharma and Aurobindo Pharma May Acquire Europen Divisions from Teva Pharma 18
Mallinckrodt May Sell Generic Drug Unit to Aurobindo Pharma 19
Aurobindo Pharma Acquires Four Biosimilar Products from TL Biopharma 20
Arrow Generiques to Acquire Select Commercial Products in France from Teva Pharma 21
Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 22
Aurobindo Pharma Completes Acquisition Of Generics Operations Of Actavis In Western Europe For US$40.8 Million 23
Aurobindo Pharma Forms Joint Venture with Tergene Biotech 25
Celon Labs Forms Joint Venture with Aurobindo Pharma 26
Aurobindo Pharma, Cipla, Desano Pharma, Emcure Pharma, Hetero Labs and Laurus Labs Enter into Licensing Agreement with Medicines Patent Pool 27
Aurobindo Pharma Extends its Licensing Agreement with Medicines Patent Pool 29
Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool 30
Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool for Lopinavir/Ritonavir 31
Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 32
Aurobindo Pharma Plans to Raise USD300 Million in Private Placement of Shares 34
Aurobindo Pharma Receives Board Approval for Private Placement of Shares for up to USD350 Million 35
Aurobindo Pharma Sells Manufacturing Facility In Tamilnadu 36
Aurobindo Pharma to Acquire Additional 20% Stake in Tergene Biotech 37
Agile Pharma Acquires Generis Farmaceutica from Magnum Capital Partners for USD142.8 Million 38
Eris Pharma Acquires Aurobindo Pharma Australia from Aurobindo Pharma 39
Aurobindo Pharma Acquires Natrol for USD132.5 Million 40
Aurobindo Pharma Acquires Hyacinths Pharma for up to USD3 Million 41
Aurobindo Pharma Acquires Remaining 25% Stake in Silicon Life Sciences from ABS Mercantiles 42
Aurobindo Pharma Ltd, Key Competitors 43
Aurobindo Pharma Ltd, Key Employees 44
Aurobindo Pharma Ltd, Other Locations 45
Aurobindo Pharma Ltd, Subsidiaries 45
Aurobindo Pharma Ltd, Joint Venture 48
List of Figures
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9